[Impact of 30 day therapy with doxazosin--alpha1 adrenergic blocker on pulmonary hemodynamics in patients with secondary pulmonary hypertension due to chronic obstructive pulmonary disease].
To prove alpha1-adrenergic hypothesis for pulmonary hypertension we studied 6 patients aged 63.3 +/- 8 (range 50-75) years with stable, advanced chronic obstructive pulmonary disease (COPD), FEV=1.51 +/- 0.3 I and with pulmonary hypertension, mean pulmonary artery pressure 28.3 +/- 8 (range 21-40) mm Hg. a1 blocker, doxazosin was administered per os in a daily dose of 2-3 mg. Pulmonary hemodynamics was performed before and after 30 day of treatment. After therapy, compared to baseline results, pulmonary artery systolic pressure decreased from 48.6 +/- 14 to 42.5 +/- 13 mm Hg, p=0.003, pulmonary artery diastolic pressure from 14.5 +/- 6 to 7 +/- 4 mm Hg, p=0.02), mean pulmonary artery pressure from 28.3 +/- 8 to 21.1 +/- 5 mm Hg, p=0.01 and pulmonary vascular resistance from 389.6 +/- 14 to 234.6 +/- 73 dyn x s x cm5. No significant changes in pulmonary artery wedge pressure, cardiac output, arterial oxygen content, percent saturation of hemoglobin with oxygen and oxygen delivery were found. In summary, the results of 30 day doxazosin therapy support alpha1 adrenergic hypothesis for pulmonary hypertension and suggest potential clinical benefits during long term treatment in patients with pulmonary hypertension due to COPD.
Oddział Kardiologiczny Wojewódzkiego Szpitala Specjalistycznego we Wrocławiu. lewczuk@wssk.wroc.pl
Jerzy
J
Lewczuk
Piotr
P
Piszko
Jacek
J
Jagas
Krzysztof
K
Wrabec
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000368:Aged; D017292:Doxazosin / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011652:Pulmonary Circulation / Q000187:drug effects*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin